Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This trial will study the effects of an investigational (not FDA approved) medication,
ROSE-010, on the movement of food through the stomach, small intestine and colon in females
with constipation predominant irritable bowel syndrome (C-IBS).
The study hypothesis is that ROSE-010 will delay gastric emptying of solids and enhances
gastric accommodation without retarding colonic transit in female patients with C-IBS.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
National Center for Research Resources (NCRR) Rose Pharma A/S